Cargando…

Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil

From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present...

Descripción completa

Detalles Bibliográficos
Autores principales: de Melo, Andréa Barbosa, da Silva, Maria da Paz C., Magalhães, Maria Cecília F., Gonzales Gil, Laura Helena Vega, Freese de Carvalho, Eduardo M., Braga-Neto, Ulisses M., Bertani, Giovani Rota, Marques, Ernesto T. A., Cordeiro, Marli Tenório
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183786/
https://www.ncbi.nlm.nih.gov/pubmed/21976581
http://dx.doi.org/10.4269/ajtmh.2011.10-0496
_version_ 1782213041205542912
author de Melo, Andréa Barbosa
da Silva, Maria da Paz C.
Magalhães, Maria Cecília F.
Gonzales Gil, Laura Helena Vega
Freese de Carvalho, Eduardo M.
Braga-Neto, Ulisses M.
Bertani, Giovani Rota
Marques, Ernesto T. A.
Cordeiro, Marli Tenório
author_facet de Melo, Andréa Barbosa
da Silva, Maria da Paz C.
Magalhães, Maria Cecília F.
Gonzales Gil, Laura Helena Vega
Freese de Carvalho, Eduardo M.
Braga-Neto, Ulisses M.
Bertani, Giovani Rota
Marques, Ernesto T. A.
Cordeiro, Marli Tenório
author_sort de Melo, Andréa Barbosa
collection PubMed
description From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).
format Online
Article
Text
id pubmed-3183786
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-31837862011-10-12 Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil de Melo, Andréa Barbosa da Silva, Maria da Paz C. Magalhães, Maria Cecília F. Gonzales Gil, Laura Helena Vega Freese de Carvalho, Eduardo M. Braga-Neto, Ulisses M. Bertani, Giovani Rota Marques, Ernesto T. A. Cordeiro, Marli Tenório Am J Trop Med Hyg Articles From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years). The American Society of Tropical Medicine and Hygiene 2011-10-01 /pmc/articles/PMC3183786/ /pubmed/21976581 http://dx.doi.org/10.4269/ajtmh.2011.10-0496 Text en ©The American Society of Tropical Medicine and Hygiene http://creativecommons.org/licenses/by/2.5/ This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
de Melo, Andréa Barbosa
da Silva, Maria da Paz C.
Magalhães, Maria Cecília F.
Gonzales Gil, Laura Helena Vega
Freese de Carvalho, Eduardo M.
Braga-Neto, Ulisses M.
Bertani, Giovani Rota
Marques, Ernesto T. A.
Cordeiro, Marli Tenório
Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title_full Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title_fullStr Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title_full_unstemmed Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title_short Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
title_sort description of a prospective 17dd yellow fever vaccine cohort in recife, brazil
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183786/
https://www.ncbi.nlm.nih.gov/pubmed/21976581
http://dx.doi.org/10.4269/ajtmh.2011.10-0496
work_keys_str_mv AT demeloandreabarbosa descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT dasilvamariadapazc descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT magalhaesmariaceciliaf descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT gonzalesgillaurahelenavega descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT freesedecarvalhoeduardom descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT braganetoulissesm descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT bertanigiovanirota descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT marquesernestota descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil
AT cordeiromarlitenorio descriptionofaprospective17ddyellowfevervaccinecohortinrecifebrazil